TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15329426
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy plus recombinant surfactant protein C-based surfactant
Study: 11583188
Drug: Targeted intra-operative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted intra-operative radiotherapy (Targit), delivered doses of 5-20 Gy over about 22 min
Study: 9820298
Drug: Computer-generated dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-generated dosing (n=137)
Study: 9820298
Drug: Traditional dosing
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional dosing (n=148)
Study: 9820298
Drug: Computer-generated dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-generated dosing (stabilisation patients)
Study: 9820298
Drug: Computer-generated dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-generated dosing (stable patients)
Study: 8548110
Drug: Amiodarone (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (low doses)
Study: 20629472
Drug: Moxifloxacin ophthalmic
Normalized name: Moxifloxacin Ophthalmic
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moxifloxacin ophthalmic solution 0.5%
Study: 12847482
Drug: FP 400
Normalized name: Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rIX-FP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FP 400 microg twice a day plus SALM 50 microg twice a day (FP 400 + SALM)
Study: 12847482
Drug: FP 1000
Normalized name: Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rIX-FP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FP 1000 microg twice a day (FP1000)
Study: 1714709
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (enoxaparin) 40.6 mg subcutaneously once daily
Study: 12244484
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (enoxaparin)
Study: 6356971
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg sublingual buprenorphine
Study: 7082534
Drug: 0.8 mg
Normalized name: biotin 0.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 mg sublingual buprenorphine
Study: 22923328
Drug: Drinkable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drinkable solution of 70 mg/100 mL alendronate
Study: 22923328
Drug: Tablets of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets of alendronate
Study: 20599461
Drug: Medications for
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medications for bipolar disorder
Study: 16238797
Drug: Inhaled steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled steroids during allergen exposure
Study: 16238797
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment during allergen exposure
Study: 12915593
Drug: CHOP plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHOP plus G‐CSF
Study: 8727431
Drug: Tidal volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tidal volume (VT) increased to 12-14 ml/kg
Study: 6339999
Drug: Potassium canrenoate
Normalized name: Potassium canrenoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium canrenoate (200 mg/day for 21 days)
Study: 6339999
Drug: Spironolactone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (200 mg/day for 21 days)
Study: 30867041
Drug: Profender® spot-on
Approvals — FDA: no, EMA: no, PMDA: no
Description: Profender® spot-on (emodepside 2.1% and praziquantel 8.6%) administered on days 0 and 14
Study: 27498023
Drug: Axitinib 5
Normalized name: axitinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axitinib 5 mg twice per day (b.i.d.; n = 192)
Study: 8255974
Drug: Isoprenaline infusion
Normalized name: isoprenaline
DrugBank: Isoprenaline (DB01064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoprenaline infusion
Study: 8963892
Drug: Edrophonium bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium bolus (10 mg)
Study: 8963892
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of factors (age, SHD, SDC, recurrent syncope)
Study: 6617274
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (MPA) 20 mg three times daily
Study: 30068518
Drug: Physical activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical activity (PA) intervention combining daily moderate intensity activities and one weekly supervised session of more strenuous activity
Study: 18087207
Drug: Systemic Family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic Family Therapy (SFT) associated with routine psychiatric treatment
Study: 18087207
Drug: Routine psychiatric
Normalized name: INVESTIGATIONAL DRUGS FOR PSYCHIATRIC DISEASE,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine psychiatric treatment alone
Study: 15866629
Drug: Basiliximab (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basiliximab (20 mg before transplantation and 20 mg on day 4)
Study: 8736467
Drug: Loading doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading doses of imipramine hydrochloride on two consecutive days
Study: 8736467
Drug: Conventional gradually
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional gradually escalating dose regimen of imipramine
Study: 1421930
Drug: Lactose-containing diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose-containing diet (6 g lactose/kg body weight/d)
Study: 3900837
Drug: Intravenous ceforanide
Normalized name: Ceforanide
DrugBank: Ceforanide (DB00923)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ceforanide
Study: 31028596
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group with medication review by a pharmacist
Study: 30515483
Drug: Implant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant treatment (Implant group)
Study: 29489098
Drug: Bolus of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus of levosimendan 24 μg/kg injected 15 min before aortic clamping.
Study: 10401195
Drug: Antiepileptic drugs
Normalized name: ANTIEPILEPTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiepileptic drugs (AED) alone
Study: 10401195
Drug: Antitubercular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antitubercular therapy and albendazole (ATB + Alb) in addition to AED
Study: 1095511
Drug: Aprotininum (Trasylol)
Normalized name: Aprotininum
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprotininum (Trasylol) 200,000 KIE infusion every 6 hours during acute alcohol withdrawal
Study: 30788869
Drug: Premature ejaculation
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Premature ejaculation desensitisation therapy combined with 30 mg dapoxetine hydrochloride (DTCD group)
Study: 23041343
Drug: Rectal cleansing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal cleansing with povidone-iodine
Study: 18004285
Drug: N-acetyl-cysteine (NAC),
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetyl-cysteine (NAC), 2 g/day for 60 days
Study: 17162624
Drug: Sertraline (50-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50-200 mg/d)
Study: 24751470
Drug: Oxandrolone (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxandrolone (0.05 mg/kg/day; max: 2.5 mg/day)
Study: 24751470
Drug: Ethinylestradiol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethinylestradiol (2 µg/day in year 1, 4 µg/day in year 2, 6/8/10 µg/day in year 3 for 4 months)
Study: 19129278
Drug: Salmeterol/fluticasone (SFP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol/fluticasone (SFP) 100/1,000 microg daily
Study: 19129278
Drug: Tiotropium/fluticasone (Tio+FP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium/fluticasone (Tio+FP) 18/1,000 microg daily
Study: 14583440
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g of essential amino acids (EAA)
Study: 11695213
Drug: New dentifrice
Approvals — FDA: no, EMA: no, PMDA: no
Description: New dentifrice formulation (Colgate Total Plus Whitening Toothpaste)
Study: 2492741
Drug: Nifedipine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (40 to 120 mg/day)
Study: 2492741
Drug: Diltiazem (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (120 to 360 mg/day)
Study: 6999946
Drug: Intravenous physostigmine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous physostigmine salicylate (2.0 mg)
Study: 26243349
Drug: Group therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group therapy module A (4 hours per week for 8 weeks)
Study: 26243349
Drug: Group therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group therapy module B (4 hours per week for 8 weeks)
Study: 26243349
Drug: Usual treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatments (control group not explicitly defined in the abstract)
Study: 25604019
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy followed by surgery (NCS group)
Study: 11923809
Drug: Sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil citrate (50 mg oral dose)
Study: 2110575
Drug: Enteral glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral glucose infusion with gastric inhibitory polypeptide
Study: 2110575
Drug: IV glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV glucose administration
Study: 31045765
Drug: Cognitive Behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavior Language Therapy (CBLT)
Study: 2107135
Drug: Pentagastrin infusion
Normalized name: pentagastrin
DrugBank: Pentagastrin (DB00183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentagastrin infusion
Study: 3371138
Drug: Indomethacin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (25 mg four times daily)
Study: 3371138
Drug: Carprofen (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carprofen (150 mg twice daily)
Study: 24076594
Drug: Calcitriol (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitriol (0.25 μg 1,25-dihydroxy cholecalciferol per capsule, 2 capsules per day)
Study: 16009883
Drug: Interferon beta‐1a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon beta‐1a 30 microg IM once weekly
Study: 16009883
Drug: Interferon beta‐1a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon beta‐1a 60 microg IM once weekly
Study: 12616704
Drug: Peginterferon alfa-2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peginterferon alfa-2a (40-kDa), 180 micrograms subcutaneous once-weekly, and ribavirin, 400 mg b.i.d. for 44 additional weeks after initial therapy
Study: 12616704
Drug: Peginterferon alfa-2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peginterferon alfa-2a (40-kDa), 180 micrograms subcutaneous once-weekly, and ribavirin, 400 mg b.i.d. for 68 additional weeks after initial therapy
Study: 12616704
Drug: Peginterferon alfa-2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peginterferon alfa-2a (40-kDa), 180 micrograms subcutaneous once-weekly, and ribavirin, 400 mg b.i.d. for 20 additional weeks after initial therapy
Study: 10357339
Drug: Clonidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (150 microg) added to 40 mL of 0.5% lidocaine
Study: 8603942
Drug: pentavalent Corynebacterium
Approvals — FDA: no, EMA: no, PMDA: no
Description: pentavalent Corynebacterium diphtheriae C7 (beta197) CRM197 protein‐conjugated pneumococcal vaccine (CV)
Study: 7199854
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of cocaine HCl solution administered intranasally
Study: 16501591
Drug: Topotecan at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan at 7 mg/m2/day
Study: 16501591
Drug: Topotecan at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan at 9.5 mg/m2/day
Study: 16501591
Drug: Topotecan at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan at 4-9.0 mg/m2/day
Study: 16501591
Drug: Topotecan at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan at 9 mg/m2/day
Study: 3651281
Drug: suxamethonium 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: suxamethonium 1 mg kg‐1
Study: 6386486
Drug: penbutolol 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: penbutolol 40 mg single dose
Study: 6386486
Drug: combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: combined therapy (penbutolol + molsidomine 2 mg single dose)
Study: 6386486
Drug: beta blocker
Normalized name: Beta blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta blocker alone
Study: 17005329
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment plus contingency management
Study: 7000243
Drug: Sustained-release oxprenolol
Normalized name: oxprenolol
DrugBank: Oxprenolol (DB01580)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustained-release oxprenolol (160 mg/day)
Study: 27450571
Drug: Psychotherapy-based text
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotherapy-based text messaging (daily messages 6 days per week for 12 weeks)
Study: 1589702
Drug: AlPO4 (preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: AlPO4 (preparation B)
Study: 3910604
Drug: Cefotaxime (dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime (dosage not specified)
Study: 29752869
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of non-HLA matched, ABO matched, unrelated allogeneic umbilical cord blood (UCB)
Study: 10102256
Drug: Sibutramine 10
Normalized name: sibutramine 10 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine 10 mg/day
Study: 19608026
Drug: Pitavastatin 4
Normalized name: PITAVASTATIN 4MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitavastatin 4 mg/day
Study: 11129008
Drug: 7-day course
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day course of oral prednisolone (10 mg/day for ages 5-11, 0.5 mg/kg for ages 12 and older)
Study: 9044556
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg ondansetron (single dose)
Study: 9044556
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg ondansetron (repetitive doses)
Study: 9044556
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg ondansetron (single dose)
Study: 1576067
Drug: Flurbiprofen administration
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flurbiprofen administration
Study: 21968663
Drug: Sertaconazole nitrate
Normalized name: Sertaconazole Nitrate
DrugBank: Sertaconazole (DB01153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertaconazole nitrate 2% cream, once daily for four weeks
Study: 15275801
Drug: Parenteral parecoxib
Normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Parenteral parecoxib sodium followed by oral valdecoxib
Study: 11439738
Drug: Standard PFD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard PFD treatment (A)
Study: 9215016
Drug: Bupivacaine 2
Normalized name: bupivacaine 29.3 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 2 mg h-1
Study: 9215016
Drug: Bupivacaine 1
Normalized name: bupivacaine 132 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 1 mg h-1
Study: 9215016
Drug: Bupivacaine 1
Normalized name: bupivacaine 132 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 1 mg h-1 combined with morphine 8 micrograms h-1
Study: 19261341
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no dental treatment)
Study: 20398111
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of both tools
Study: 15665343
Drug: Atropine eye
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine eye drops (once daily for 2 years)
Study: 15665343
Drug: Placebo eye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo eye drops (once daily for 2 years)
Study: 12947054
Drug: Cisplatin 100
Normalized name: CISPLATIN 100MG/VIL (PF) INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 100 mg/m2 day 1 plus gemcitabine 1,000 mg/m2 and vinorelbine 25 mg/m2 days 1 and 8, every 3 weeks for six cycles (CGV)
Study: 28834836
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment group (n = 32)
Study: 25714415
Drug: Lidocaine injection
Normalized name: lidocaine Injection
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine injection plus physiotherapy (INJPT)
Study: 22082443
Drug: 1500 iu
Normalized name: Vitamin E 1500 IU/30 GM Topical application Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 iu hCG and a single dose of 50 mg dexamethasone
Study: 22082443
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (110 cycles without treatment)
Study: 19012048
Drug: Capsicum oleous
Normalized name: Capsicum
DrugBank: Capsicum (DB10897)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsicum oleous nasal spray, 4 microg/puff, three times a day for 3 consecutive days
Study: 9059063
Drug: Remission induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remission induction therapy (AVC) with terarubicin (THP‐ADR), vincristine, and continuous infusion of cytosine arabinoside (Ara C) for 32 or 48 weeks.
Study: 9059063
Drug: VP16 +
Approvals — FDA: no, EMA: no, PMDA: no
Description: VP16 + high dose Ara C used sequentially for 32 or 48 weeks.
Study: 8458096
Drug: Both GH
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both GH treatment groups
Study: 3724995
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (6 weeks)
Study: 3724995
Drug: Reinstituted lithium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reinstituted lithium treatment (6 weeks)
Study: 3724995
Drug: Continuous lithium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous lithium medication (replication study)
Study: 24170757
Drug: Self-titration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-titration of bolus insulin glulisine
Study: 24170757
Drug: Physician titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician titration of bolus insulin glulisine
Study: 20137090
Drug: Tight blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tight blood glucose control using insulin by intravenous infusion titrated to maintain BG between 4 and 7.0 mmol/l.
Study: 7167734
Drug: 25 mg/day
Normalized name: estradiol 0.025 MG/Day Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg/day of trimipramine
Study: 30854569
Drug: Preoperative bleeding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative bleeding of more than 250 mL
Study: 17548727
Drug: Low cotinine
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low cotinine group (cotinine between 0.2 and 1.6 ng/mL)
Study: 17548727
Drug: Top decile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Top decile cotinine group (cotinine ≥ 1.7 ng/mL)
Study: 15602499
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg gaboxadol hydrochloride
Study: 11966623
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose (81 mg) of intravesical bacille Calmette-Guérin (BCG)
Study: 9818881
Drug: Oral branched-chain
Normalized name: Machilus thunbergii branch extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral branched-chain amino acids (BCAAs) at a dosage of 77 mg/kg
Study: 3296962
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily insulin
Study: 3289293
Drug: Multiple insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multiple insulin injections
Study: 7032642
Drug: Pre-operative serum
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-operative serum antisperm antibody titre of 512 or more
Study: 7032642
Drug: Pre-operative serum
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-operative serum antisperm antibody titre below 512
Study: 7032642
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of seminal plasma antibodies
Study: 12686336
Drug: Diet-only treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet-only treatment
Study: 10226960
Drug: Pain medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain medication status before surgery
Study: 29499287
Drug: Placebo (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical injections)
Study: 27465383
Drug: Infant formula
Normalized name: Infant formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infant formula milk (IFM) containing 10.5 μg I/100 kcal
Study: 27465383
Drug: Infant formula
Normalized name: Infant formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infant formula milk (IFM) containing 19.3 μg I/100 kcal
Study: 20720259
Drug: 2.0 mg
Normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg GLP-1
Study: 20720259
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg PYY3-36
Study: 18789007
Drug: Acridilol for
Normalized name: Acridinyl anisidide
DrugBank: Amsacrine (DB00276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acridilol for 24 weeks with other antihypertensive therapy (n=291)